Bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma hyopneumoniae and preparation method of bigeminy inactivated vaccine

A technology of mycoplasma hyopneumoniae and dual inactivated vaccines, which is applied in the fields of virus antigen components, antiviral agents, and pharmaceutical formulations, can solve the problem of no porcine circovirus mycoplasma hyopneumoniae dual combination vaccine, etc., and achieve a long duration of immunity , less time-consuming, and cost-reducing effects

Active Publication Date: 2013-06-05
PU LIKE BIO ENG +1
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no domestically produced inactivated vaccine for Mycoplasma suis pneumonia, and the Mhp inactivated vaccine products registered abroad mainly include the BQ14 strain (pig Kechuan) of Merial, France, and the J strain (Anbaike) of Schering-Plough (Intervet) of the United States. ), the J strain (Xikeshu) from Spain's Haibolai Biopharmaceutical Factory, the Ruifute from Pfize

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma hyopneumoniae and preparation method of bigeminy inactivated vaccine
  • Bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma hyopneumoniae and preparation method of bigeminy inactivated vaccine
  • Bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma hyopneumoniae and preparation method of bigeminy inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1, the preparation of porcine circular ring, mycoplasma pneumoniae dual combination inactivated vaccine

[0029] 1. The source of bacteria (virus) strains

[0030] The selected porcine circovirus strain is the PCV-2b strain SH strain, which has been preserved in the General Microbiology Center of the China Microbiological Culture Collection Management Committee. The preservation date: March 4, 2008, and the preservation number is CGMCC No.23890 .

[0031] The selected strain of Mycoplasma hyopneumoniae was CVCC355, which was purchased from China Veterinary Drug Control Institute.

[0032] 2. Preparation and inspection of vaccine semi-finished products

[0033] 2.1 Preparation of seeds for production

[0034] 2.1.1 Preparation of porcine circovirus type 2: Dilute the virus seeds appropriately with breastmilk liquid, inoculate PK15 cells (purchased from China Veterinary Drug Control Institute) at 5% for culture, absorb at 37°C for 30 minutes, add 4% Calf seru...

Embodiment 2

[0076] Example 2, the comparison of the immune protection effect and the serological effect of the dual inactivated vaccine product trial-produced in Example 1 and two kinds of monovalent inactivated vaccines (mycoplasma hyopneumoniae inactivated vaccine or porcine circovirus type 2 inactivated vaccine) evaluate

[0077] In 1 material embodiment 1, the dual inactivated vaccine trial product of porcine circovirus type 2 and mycoplasma hyopneumoniae; porcine circovirus type 2 inactivated vaccine (SH strain), produced by Pulaike Bioengineering Co., Ltd. (batch number 100903); American Schering-Plough Inactivated Vaccine for Mycoplasma Porcine Pneumonia (J strain) (batch number 100806).

[0078] 2 Animal experiment design

[0079]Select 70 weaned piglets aged 21-28 days and divide them into 7 groups, 10 pigs in each group (see the table below); each pig in the 1st and 2nd groups was intramuscularly injected with porcine ring and Mycoplasma pneumoniae dual inactivated vaccine 1ml...

Embodiment 3

[0110] Research on the duration of immunity of trial-produced products in Example 3 and Example 1

[0111] In 1 material embodiment 1, the dual inactivated vaccine trial product of porcine circovirus type 2 and mycoplasma hyopneumoniae; porcine circovirus type 2 inactivated vaccine (SH strain), produced by Pulaike Bioengineering Co., Ltd. (batch number 100903); American Schering-Plough Inactivated Vaccine for Mycoplasma Porcine Pneumonia (J Strain) (Lot No. 100806)

[0112] 2 Animal experiment design

[0113] Select 70 weaned piglets aged 21 to 28 days and divide them into 7 groups with 10 piglets in each group. See the table below for the grouping treatment:

[0114]

[0115]

[0116] Note:

[0117] A, vaccine 1 is porcine circovirus type 2 inactivated vaccine trial product in embodiment 1, Mycoplasma pneumoniae dual inactivated vaccine; Vaccine 2 is porcine circovirus type 2 inactivated vaccine (SH strain), produced by Pulaike Bioengineering Co., Ltd. ( The batch nu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma pneumoniae and a preparation method of the bigeminy inactivated vaccine. The bigeminy inactivated vaccine comprises inactivated porcine circovirus type 2, inactivated swine mycoplasma pneumoniae, a vaccine adjuvant, and an excipient, wherein the content of the porcine circovirus type 2 is at least105.5 tissue culture inoculated dose (TCID) 50/head, and the content of the swine mycoplasma pneumoniae is at least 2*109 MHDCE/head. The bigeminy inactivated vaccine has the advantages that the immune effect is equal to or better than the effect of sum of commodity single vaccines in the market, two antigens do not interfere each other, immune persistent period is long, potency is lasting, and due to the fact that one time immunization only needs, cost is lowered, and stress reaction of animals is also reduced. The bigeminy inactivated vaccine can be used for preventing porcine circovirus disease and at the same time preventing the swine mycoplasma pneumoniae.

Description

technical field [0001] The invention relates to a dual inactivated vaccine of porcine circovirus type 2 and mycoplasma pneumoniae and a preparation method thereof, belonging to the field of veterinary vaccines. Background technique [0002] Porcine circovirus (abbreviation: PCV) is the smallest animal virus found so far, with an average diameter of 17nm. According to the difference of pathogenicity, antigenicity and nucleotide sequence of porcine circovirus, PCV is divided into two genotypes, non-pathogenic PCV-1 and pathogenic PCV-2. PCV-2 is the main pathogen of postweaning multisystemic wasting syndrome (Postweaning Multisystemic Wasting Syndrome, PMWS). The disease was first discovered in Canada (1991), and soon occurred and spread in some countries in Europe, America and Asia, including my country. In addition to PMWS, PDNS (porcine dermatitis and nephrotic syndrome), PNP (proliferative necrotizing pneumonia), PRDC (porcine Respiratory disease syndrome), reproductive d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/295A61P31/20A61P31/04A61K39/12
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap